Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07762248
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular Permanent Molars With Necrotic Pulp and Apical PeriodontitisMohamed Ashraf AbdeenNot Yet RecruitingPhase 2
NCT07762248Not Yet Recruiting
Phase 2
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular...Mohamed Ashraf Abdeen
NCT07764146
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseVoyager TherapeuticsNot Yet RecruitingPhase 1
NCT07764146Not Yet Recruiting
Phase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheim...Voyager Therapeutics
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07763613
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education and Research HospitalNot Yet Recruiting
NCT07763613Not Yet Recruiting
—
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education...
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07763262
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha UniversityCompletedNot Applicable
NCT07763262Completed
Not Applicable
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha University
NCT07762833
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisGalderma R&DNot Yet RecruitingPhase 3
NCT07762833Not Yet Recruiting
Phase 3
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub...Galderma R&D
NCT07763158
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent Pain in Patients With Severe Knee OsteoarthritisKing Abdullah International Medical Research CenterRecruitingNot Applicable
NCT07763158Recruiting
Not Applicable
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent...King Abdullah Internation...
NCT07762469
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin XuNot Yet Recruiting
NCT07762469Not Yet Recruiting
—
Diagnostic Performance of a Flexible Penile Monitoring System for EDBin Xu
NCT07762573
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective StudyNanfang Hospital, Southern Medical UniversityRecruiting
NCT07762573Recruiting
—
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment i...Nanfang Hospital, Souther...
NCT07763132
Comparison of Virtual Reality, EMLA Cream, and Standard Care for Pain During Blood Draws in ChildrenMarie LulkováRecruitingNot Applicable
NCT07763132Recruiting
Not Applicable
Comparison of Virtual Reality, EMLA Cream, and Standard Care for Pain During Blo...Marie Lulková
NCT07763548
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection PainErasme University HospitalNot Yet RecruitingPhase 4
NCT07763548Not Yet Recruiting
Phase 4
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Mini...Erasme University Hospita...
NCT07763730
Effects of Robotic Pet and Video-Based Distraction on Pain, Fear, and Anxiety in Children During VenipunctureAkdeniz UniversityCompletedNot Applicable
NCT07763730Completed
Not Applicable
Effects of Robotic Pet and Video-Based Distraction on Pain, Fear, and Anxiety in...Akdeniz University
NCT07762586
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)Rutgers, The State University of New JerseyRecruitingPhase 2
NCT07762586Recruiting
Phase 2
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NA...Rutgers, The State Univer...
NCT07763314
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022Cantonal Hospital of St. GallenCompleted
NCT07763314Completed
—
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Can...Cantonal Hospital of St....
NCT07762261
Impact of Generative AI on University Students' Learning Processes and Critical ThinkingAtaturk UniversityNot Yet RecruitingNot Applicable
NCT07762261Not Yet Recruiting
Not Applicable
Impact of Generative AI on University Students' Learning Processes and Critical...Ataturk University
NCT07762391
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinary IncontinenceKaramanoğlu Mehmetbey UniversityCompletedNot Applicable
NCT07762391Completed
Not Applicable
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinar...Karamanoğlu Mehmetbey Uni...
Result Breakdown
Not yet recruiting9 (45%)
Recruiting5 (25%)
Completed5 (25%)
Unknown1 (5%)
not_applicable7 (35%)
Not Specified6 (30%)
Phase 13 (15%)
Phase 22 (10%)
Phase 31 (5%)
Phase 41 (5%)